评论
打印
Chief Executive of Pfizer Pharmaceuticals, Ian Read, has been obsessed with finding a tax “inversion” deal for at least two years.
至少在过去两年，辉瑞首席执行官伊恩·瑞德一直对促成“税负倒置”情有独钟。
He tried AstraZeneca but lost the takeover bid in an embarrassing fashion.
辉瑞曾对阿斯利康表示收购意向，但却尴尬收场。
Then, he tried to acquire GlaxoSmithKline, but got nowhere.
随后又向葛兰素史克伸出橄榄枝，但最终无果。
Now he’s landed on Allergan, the Botox firm that is the biggest Irish company that nobody knew was Irish.
如今又中意肉毒杆菌生产商艾尔建，艾尔建是爱尔兰最大制药公司，但却没人知道他们来自爱尔兰。
Pfizer anticipates that the combined company will have an adjusted effective tax rate of approximately 17%-18%.
据辉瑞预计，新公司税率预计下调至17%-18%。
That’s the logic of the deal a previous 26% tax rate that falls to close to 17%.
之前的26%税率也有望下调至近17%。
译文属可可英语原创，未经允许，不得转载。
